Attaya Suvannasankha MD
Hematologic Oncology
Associate Professor, Medicine, Indiana University School of Medicine
1030 W. Michigan St.2nd FloorIndianapolis, IN 46202
Overview of Dr. Suvannasankha
Dr. Attaya Suvannasankha is an oncologist in Indianapolis, IN and is affiliated with multiple hospitals in the area, including Indiana University Health University Hospital, Indiana University Health North Hospital, Select Specialty Hospital of INpolis, Eskenazi Health, and Richard L. Roudebush Veterans Affairs Medical Center. She received her medical degree from Chulalongkorn University Faculty of Medicine and has been in practice 30 years. Dr. Suvannasankha accepts several types of health insurance, listed below. She is one of 12 doctors at Select Specialty Hospital of INpolis and one of 43 doctors at Eskenazi Health who specialize in Oncology. She has more than 60 publications and over 500 citings.
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 2000 - 2003
Jefferson Health Medical Education/Jefferson Einstein Philadelphia HospitalResidency, Internal Medicine, 1997 - 2000
Chulalongkorn University Faculty of MedicineClass of 1996
Certifications & Licensure
IN State Medical License 2003 - 2027
PA State Medical License 1998 - 2000
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2015-2016
- CMS Meaningful Use Stage 1 Certification FirstNet (Clinical), Cerner Corporation, 2015-2016
- CMS Meaningful Use Stage 1 Certification PathNet, Cerner Corporation, 2015-2016
Clinical Trials
- Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma
- Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
- Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma Start of enrollment: 2010 Aug 27
Publications & Presentations
PubMed
- 1 citationsSGLT-2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma.Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha
European Journal of Haematology. 2026-11-01 - Geographic Variation and Inequities in Burden and Access to CAR T-Cell Therapies for Multiple Myeloma in the US.Brandon J Blue, Andrew K ElHabr, Benjamin A Derman, Avik Ray, Jie Ting
Clinical Lymphoma, Myeloma & Leukemia. 2026-10-01 - Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study.Attaya Suvannasankha, Mengying Li, Omonefe Omofuma, Christian Hampp, Matthew Phelan
Clinical Cancer Research. 2026-09-15
Press Mentions
First-in-Human Multiple Myeloma Study Shows 90 Percent Response RateApril 19th, 2023- Early Data Indicates New Therapy Is ‘Safe and Effective’ for Cancer Metastases in BonesApril 29th, 2021
Purdue Researchers at Work on Anemia App to Make Detection EasierNovember 30th, 2017
Grant Support
- Preclinical Validation of Adjuvant Fingolimod to Increase Efficacy of Proteasome Inhibitors for Treatment of Multiple MyelomaRLR VA MEDICAL CENTER2024–2028
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS California PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPOGreat West PPO
Health Net California Large Group PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: